Co-Diagnostics, Inc. Common Stock (CODX) - Total Liabilities
Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has total liabilities worth $5.46 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Co-Diagnostics, Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
Co-Diagnostics, Inc. Common Stock - Total Liabilities Trend (2014–2025)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Co-Diagnostics, Inc. Common Stock asset portfolio.
Co-Diagnostics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Centogene N.V.
NASDAQ:CNTGF
|
USA | $102.44 Million |
|
Omnia Metals Group Ltd
AU:OM1
|
Australia | AU$276.32K |
|
PROSPECT RIDGE RESOURCES
F:0ED
|
Germany | €445.65K |
|
VivoSim Labs, Inc.
NASDAQ:VIVS
|
USA | $6.19 Million |
|
Alvo Minerals Ltd
AU:ALV
|
Australia | AU$471.67K |
|
Pool Safe Inc
V:POOL
|
Canada | CA$2.20 Million |
|
Fancy Wood Industries Public Company Limited
BK:FANCY
|
Thailand | ฿33.48 Million |
|
Central Asia Metals Plc
LSE:CAML
|
UK | GBX94.63 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Co-Diagnostics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Co-Diagnostics, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Co-Diagnostics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Co-Diagnostics, Inc. Common Stock (2014–2025)
The table below shows the annual total liabilities of Co-Diagnostics, Inc. Common Stock from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.11 Million | -57.54% |
| 2024-12-31 | $9.69 Million | +4.09% |
| 2023-12-31 | $9.31 Million | +8.65% |
| 2022-12-31 | $8.57 Million | -66.48% |
| 2021-12-31 | $25.56 Million | +462.89% |
| 2020-12-31 | $4.54 Million | +849.80% |
| 2019-12-31 | $478.07K | -81.70% |
| 2018-12-31 | $2.61 Million | +221.75% |
| 2017-12-31 | $811.80K | -81.08% |
| 2016-12-31 | $4.29 Million | +182.58% |
| 2015-12-31 | $1.52 Million | +1152.55% |
| 2014-12-31 | $121.22K | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more